The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -4,801,149 | -7,649,189 |
| Stock-based compensation | -152,421 | -318,193 |
| Change in fair value of derivative liabilities | 67,039 | - |
| Prepaid expenses and other receivable | 232,968 | -559,928 |
| Accounts payable - related party | -2,523 | 3,719 |
| Other payables and accrued liabilities | -35,152 | -90,993 |
| Accrued liability - related party | 4,125,000 | 5,981,666 |
| Franchise tax payable | 0 | -4,134 |
| Income tax payables | 0 | -50 |
| Net cash used in operating activities | -727,332 | -880,860 |
| Payments of transactions cost | 12,652 | 40,000 |
| Proceeds from issuance of common stock for pipe investment | 1,050,000 | 1,350,000 |
| Purchase of treasury stock | 0 | 29,462 |
| Net cash provided by (used in) financing activities | 1,037,348 | 1,280,538 |
| Net change in cash | 310,016 | 399,678 |
| Cash and cash equivalents at beginning of period | 916,916 | - |
| Cash and cash equivalents at end of period | 1,626,610 | - |
Estrella Immunopharma, Inc. (ESLA)
Estrella Immunopharma, Inc. (ESLA)